Episodes
-
Proton pump inhibitors have long been the mainstay of treatment for gastroesophageal reflux disease (GERD), dating back to omeprazole (Prilosec)’s initial approval in 1989. However, the treatment landscape has undergone its first major changes in the past 30 years with the emergence of vonoprazan (Voquezna).
A novel, first-in-class small molecule potassium-competitive acid blocker (PCAB), vonoprazan now boasts 3 US Food and Drug Administration (FDA) approvals across both erosive and non-erosive GERD. Less than a year after earning approval for the healing and maintenance of healing of all grades of erosive GERD as well as the relief of heartburn associated with erosive GERD, vonoprazan has also been approved for the treatment of heartburn in non-erosive GERD. -
Led by a flood of biologic therapies becoming available and progressing within the therapeutic pipeline, the field of dermatology finds itself in the midst of a watershed moment for many dermatologic conditions. To celebrate and recap the advancements occurring in the first half of 2024, the editorial team of HCPLive Dermatology sat down with James Del Rosso, DO, research director of JDR Dermatology Research and president of the American Acne and Rosacea Society, for more perspective on pipeline movement.
Del Rosso, who also serves as an adjunct clinical professor of Dermatology at Touro University, takes a deep dive into several different disease states in dermatology and highlights how the news to emerge in the last 6 months, as well as prior to the close of 2023, has influenced real-world management. -
Episodes manquant?
-
In the latest episode of New Insight with Veeral Sheth, MD, host Veeral Sheth, MD, director of clinical research at University Retina, speaks with Seemi Khan, chief medical officer at Alkeus Pharmaceuticals, on the company’s lead candidate being evaluated in clinical trials for the treatment of Stargardt disease and geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Gildeuretinol is a novel molecule designed as a specialized form of deuterated vitamin A to reduce the dimerization of vitamin A without disrupting vision. The therapy has received Breakthrough and Orphan Drug designations from the US Food and Drug Administration (FDA).
Listen to the conversation between experts on Khan’s background in the pharmaceutical industry, including time spent at Abbott, Abbvie, and Quark Pharmaceuticals, her experience bringing treatments to patients with rare diseases, and the impressive data from gildeuretinol in the TEASE clinical trial program for a currently unmet need.
Episode Highlights
0:07 Episode Intro
0:57 Seemi Khan's background
4:38 Mechanism of action of gildeuretinol
7:22 Patient populations
9:00 TEASE clinical trial program
14:37 Gildeuretinol in GA
16:32 Safety data
18:47 Next steps for Alkeus
22:28 Conclusion
Check out more ophthalmology coverage at HCPLive.com! -
Since the mid-20th century ushered in the ‘Information Age’, a desire for innovation has driven the pursuit of technological advancements. Many may immediately consider the transformations personal computers and smartphones have had on modern society, but these advancements have transformed the fields of medicine time and time again.
In the latest episode of New Insight with Veeral Sheth, MD, Michael Freeman, the chief executive officer of Ocutrx, joins Dr. Sheth to discuss the history of Ocutrx, its OcuLez and OR-Bot products, and what he envisions in the next decade at the company.
Episode Highlights
0:06 Introduction
1:22 History of Ocutrx
9:05 A look at the Oculenz
18:27 Introduction of a caretaker app
19:26 A look at the OR-Bot
25:55 Envisioning the next decade at Ocutrx
29:02 Conclusion
Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at [email protected]. -
Episode Highlights:
0:16 Intro
0:28 Overview of presentation
0:38 Acne and post-inflammatory hyperpigmentation
01:35 Approaches to take
03:21 Rosacea, use of dermoscopy and symptomatology assessment
04:59 Necessity of inclusivity in clinical trials, other knowledge gaps
06:05 Images used in education
The American Academy of Dermatology (AAD) Annual Meeting in 2024 featured Dr. Andrew Alexis, a prominent figure in dermatology. Dr. Alexis, currently serving as the vice-chair for diversity in the department of dermatology and a professor of clinical dermatology at Weill Cornell Medical College in New York, presented a talk titled "Controversies in Acne and Rosacea."
In the interview, he shed light on critical aspects of managing acne and rosacea, particularly focusing on patients with skin of color.
Dr. Alexis advocated for inclusivity in clinical trials to improve understanding across diverse patient populations. He stressed the importance of expanding public awareness of rosacea in communities with skin of color and suggested incorporating diverse images into educational materials to better represent the spectrum of affected individuals.
Dr. Alexis's insights underscore the necessity of tailored approaches and increased inclusivity in dermatological research and education to better serve patients with diverse skin tones and backgrounds.
For additional information covered at the 2024 AAD conference, visit us at: https://www.hcplive.com/conference/aad. -
In the medical community, a revolving cast of players plays a pivotal role in advancing scientific discovery and enhancing patient outcomes. During the research stage, a collaborative team effort, from the clinical trial sponsors to research sites and patient populations, is essential to ensure smooth progress and sustain momentum toward the finish line.
The latest episode of New Insight with Veeral Sheth, MD features a conversation with Brad Doerschuk, the CEO of InFocus Clinical Research, on the important role of contract research organizations (CROs) in retina and the field of ophthalmology.
In their conversation, Sheth and Doerschuk shed light on the role of CROs in managing clinical trials, dive into the evolution of the retina space in recent decades, and describe the challenges in recruiting for trials of new agents.
Episode Highlights
0:00 Introduction
0:52 What is a CRO?
2:13 Development of InFocus
6:45 Discussing the retina pipeline
11:46 Recruitment challenges, solutions
15:50 Developing new clinical trial sites
18:19 Relationship between investigators, CROs
19:56 Shift in FDA guidance
23:14 New trial endpoints
25:16 Conclusion
Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at [email protected]. -
A special double-episode of New Insight with Veeral Sheth, MD features a well-rounded conversation on all things ophthalmology with returning guest David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida, as well as first-time guest Roger Goldberg, MD, a vitreoretinal surgeon at Bay Area Retina Associates.
The trio of retina specialists discuss recent conference news, the anniversary of a landmark agent, and what’s to come in 2024 for the specialty.
Episode Highlights:
0:00 Introduction
1:25 Entering 2024
7:34 The importance of treatment efficacy
12:09 Re-engaging GA treatment
15:05 Comparing aflibercept 8 mg and faricimab
23:00 Real-world data sets
26:30 What’s to come in 2024
27:45 Intravitreal gene therapies
31:00 Port delivery system
36:00 Wrapping-up
Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at [email protected]. -
In every episode of New Insight, Veeral Sheth, MD, Director of Clinical Trials at University Retina in Chicago, takes an in-depth look at the biggest news in ophthalmology and the behind the scenes work involved in eye care, with a rotation of guest experts involved in ophthalmic research, development, and clinical care.
The latest episode of New Insight features a conversation with Ocuphire Pharma’s CEO on the company’s flagship retinal product and leading a small, but high-powered research team.
Episode Highlights:
0:04 Introduction
1:23 History of Ocuphire Pharma
3:50 Leading a small, high-functioning team
6:41 Magrath’s background and journey
11:02 APX3330 for Diabetic Retinopathy
15:20 2024 Plans for Ocuphire
18:53 Addressing unmet needs
20:20 Outro
Every episode of New Insight is available on HCPLive.com and be sure to subscribe to our channel on Spotify and Apple Podcasts. Please direct any podcast-related inquiries to show producer Connor Iapoce at [email protected]. -
On the floor at AAO 2023, host Veeral Sheth, MD, and producer Connor Iapoce discuss UBX1325 for patients with diabetic macular edema, based on the 48-week results from the phase 2 BEHOLD study.
Episode Highlights:
0:30 Introduction
0:48 Background into UBX1325 and BEHOLD
2:49 BEHOLD 48-week results
6:05 Next steps
6:56 Conclusion
Please direct any podcast-related inquiries to [email protected]. -
Episode Highlights
0:12 Intro
1:24 Challenges in autoimmune hepatitis
3:30 Patient demographics
4:25 Diagnostic challenges
6:35 What is overlap syndrome?
8:04 Mysteries behind immune dysregulation
9:05 Promising drugs in investigation
10:51 The BAFF receptor target
11:41 Infliximab & rituximab
12:38 An autoimmune hepatitis wishlist
15:29 Outro
Autoimmune hepatitis (AIH), a rare liver disease characterized by an unclear driver of inflammation, is historically challenged by limited clinical understanding, a slow development of treatment options in investigation, and a nonetheless concerning prognosis for affected adults and children.
While some prospects are in development to aid specialists in adequately identifying risk factors for, diagnosing and treating AIH, education and communication on those developments is vital.
In an interview with HCPLive during the American College of Gastroenterology (ACG 2023) Annual Scientific Meeting in Vancouver, BC this week, Gina Choi, MD, associator clinical professor of medicine and surgery at UCLA Health, discussed the ins and outs of modern autoimmune liver disease research and development.
Including the treatment pipeline and current standards for diagnostics, Choi additionally discussed the sociodemographic and pathophysiological traits of AIH burden—as well as the lesser-known overlap syndrome.
For more hepatology and gastroenterology coverage from ACG 2023, visit us at https://www.hcplive.com/conference/acg. -
Host Veeral Sheth, MD is joined by Megan Baldwin, PhD, CEO and Managing Director of Opthea Limited, to discuss OPT-302 or sozinibercept, the company's novel anti-VEGF-C / VEGF-D treatment for wet AMD and other retinal diseases.
Episode Highlights:
0:06 Introduction
0:37 Background of Dr. Baldwin
9:56 Promising data on OPT-302/sozinibercept
16:39 Making decisions as a clinician, industry leader
22:11 Future of the treatment landscape
28:24 What’s next for Opthea?
32:39 Conclusion
Please direct any podcast-related inquiries to [email protected]. -
Warren Jones, PhD, scientific founder of EarliTec Diagnostics and autism expert, discusses his team's development of an eye-tracking device recently authorized by the FDA and proven in clinical trials to predict autism consistent with expert diagnoses.
-
After a historically low-transmission summer, new cases, hospitalizations and deaths due to COVID-19 have increased by approximately 18% in the US over the last week, according to CDC data.
In a new DocTalk interview, Donald J. Alcendor, PhD, associate professor, department of pathology microbiology and immunology, division of infectious diseases, Vanderbilt University Medical Center, and HCPLive Editorial Advisory Board member, discussed the factors influencing the current iteration of COVID-19 in the US. Put briefly: “The virus is changing, and immunity is waning.”
Want more COVID-19 and health care news updates? Visit us at HCPLive.com.
Episode highlights:
0:16 Intro
1:36 The current climb in COVID-19: What’s happening?
3:58 Are the variants becoming harder to dodge?
7:01 How the end of the US public health emergency impacted prevention
11:07 Realistic vaccine expectations
13:13 Advancing COVID-19 antivirals
17:32 The future for mRNA vaccines infectious disease
21:27 Public health implications
22:58 A quiet COVID-19 summer: What went well?
25:06 Projecting future waves
28:26 Advice for clinicians in preparing patients -
In this episode, host Veeral Sheth, MD, and producer Connor Iapoce discuss 5 important presentations from ASRS 2023. The discussion centers around new data on geographic atrophy therapies, novel agents for DME, and the feasibility of home OCT.
Please direct any podcast-related inquiries to [email protected]. -
The newest episode of New Insight with Veeral Sheth, MD features a conversation with David Eichenbaum, MD, the director of research for Retina Vitreous Associates of Florida. A seasoned clinical trial investigator and a friendly face at major medical meetings, Eichenbaum provides insights into his goals behind mentorship and inspiring others, sharing anecdotes about his own journey. On the heels of an already busy year, the experts discuss evolutions in the field and the pipeline, as the retina landscape changes each calendar month. In this vein, the two specialists discuss their ever-changing roles from investigators to mentors to stewards for the next generation of retina specialists.
Please direct any podcast-related inquiries to show producer Connor Iapoce at [email protected]. -
In the latest episode of New Insight, Veeral Sheth, MD sat down with Cedric Francois, MD, PhD, co-founder and chief executive officer/president of Apellis Pharmaceuticals. The two experts discussed the company's landmark therapy, pegcetacoplan (SYFOVRE™), for geographic atrophy and the decades-long journey toward FDA approval. Sheth also asked about Francois' evolving role in the company and the interplay between being a scientist, clinician, and corporate executive. The experts also touched on how the GA treatment landscape might evolve over the next few years and what will shape the future of retina.
Please direct any podcast-related inquiries to [email protected]. -
In this episode, Veeral Sheth, MD, sits down with Jay Duker, MD, the president and chief operating officer of Eyepoint Pharmaceuticals, for a discussion on his storied career in ophthalmology, the importance of fostering a relationship between clinicians and industry, and the current biotech Dr. Duker and team are working on at Eyepoint.
Please direct any podcast-related inquiries to [email protected]. -
In this episode, Charles Wykoff, MD, PhD joins Dr. Sheth to provide insight into the recent landmark approval of pegcetacoplan injection (SYFOVRE™) for geographic atrophy, how clinical practice has changed as a result, and both the early struggles with and optimism for an ever-changing treatment landscape.
Please direct any podcast-related inquiries to [email protected]. -
As part of our ARVO 2023 coverage, Dr. Sheth sat down with Pravin Dugel, MD, President of Iveric Bio. Together, the experts discussed the lead molecule for the company, avacincaptad pegol for geographic atrophy, and touched on the data being presented at the conference, as well as a look back at Dugel's career and his transition into industry.
-
The inaugural episode of New Insight with Veeral Sheth, MD, our premier ophthalmology-focused podcast, features a conversation with Arshad Khanai, MD, the Director of Clinical Research at Sierra Eye Associates in Reno, Nevada.
Together, our experts discuss their background and education in retina, and how they started working on clinical trials. They go on to describe the work that has led to recent landmark drug approvals in ophthalmology, including faricimab and pegcetacoplan, and the impact of these treatments on patients.
Friends and colleagues for nearly 20 years, Sheth and Khanani talk a bit about their history, what mentorship means in medicine and their role as mentors to fellows and younger colleagues within the space.
Lastly, the two KOLs discuss what they are looking forward to in the year, with particular mention of upcoming meetings and developments that may define the year 2023.
We hope you enjoy our first episode! Keep an eye out for more from New Insight. - Montre plus
